---
title: "Bezuclastinib in Nonadvanced systemic mastocytosis: References"
description: "Reference list for the formulary evidence report on Bezuclastinib in Nonadvanced systemic mastocytosis. 63 cited documents."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Nonadvanced systemic mastocytosis: References

<a id="references"></a>

## 5 References

1. [AAAAI (2025)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2025-Summit.pdf)
2. [AAAAI (2026)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2026-Summit-Bone.pdf)
3. [Akin (2023)](https://pubmed.ncbi.nlm.nih.gov/37758410/)
4. [Akin et al. (2026a)](https://www.jacionline.org/article/S0091-6749%2825%2901699-9/fulltext)
5. [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/)
6. [ASH (2022)](https://www.cogentbio.com/wp-content/uploads/2022/12/ASH-2022-Summit-TiP.pdf)
7. [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)
8. [Blood (2023)](https://scholars.duke.edu/publication/1664410)
9. [Boggs et al. (2026)](https://www.jacionline.org/article/S0091-6749%2825%2901708-7/fulltext)
10. [Bose et al. (2026)](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650%2826%2902411-0/fulltext)
11. [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)
12. [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)
13. [Canada’s Drug Agency avapritinib reimbursement review report (2026)](https://canjhealthtechnol.ca/index.php/cjht/article/download/PC0416r/PC0416r/14024)
14. [Chifotides and Bose (2025)](https://pubmed.ncbi.nlm.nih.gov/39168723/)
15. [ClinicalTrials.gov NCT05186753](https://clinicaltrials.gov/study/NCT05186753)
16. [Cogent Biosciences](https://www.cogentbio.com/bezuclastinib/)
17. [Cogent Biosciences 2026 AAAAI additional SUMMIT data announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-highlights-additional-data-six-bezuclastinib)
18. [Cogent Biosciences 2026 AAAAI SUMMIT posters announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-multiple-summit-posters-2026-aaaai)
19. [Cogent Biosciences AdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-1)
20. [Cogent Biosciences Breakthrough Therapy designation announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-breakthrough-therapy)
21. [Cogent Biosciences first quarter 2026 financial results (2026)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)
22. [Cogent Biosciences investor overview](https://investors.cogentbio.com/)
23. [Cogent Biosciences NonAdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-application)
24. [Cogent Biosciences NonAdvSM new drug application submission announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application)
25. [Cogent Biosciences presentation (2024)](https://investors.cogentbio.com/static-files/6c1e88e8-fd51-40f6-8b0f-dddc6ca28dc2)
26. [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)
27. [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)
28. [Cogent Biosciences SUMMIT full results announcement at ASH (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-presents-full-summit-results-bezuclastinib)
29. [Cogent Biosciences SUMMIT top-line results announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-top-line-results-achieving)
30. [Cogent Biosciences third quarter 2026 financial results (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-12)
31. [Costa et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37256917/)
32. [Costanzo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40471046/)
33. [Dana-Farber Cancer Institute](https://www.dana-farber.org/clinical-trials/22-592)
34. [Fahrenholz et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.527)
35. [Farmer and Radia (2024)](https://pubmed.ncbi.nlm.nih.gov/39187708/)
36. [FDA orphan drug designation record for avapritinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=506515)
37. [FDA orphan drug designation record for bezuclastinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=929722)
38. [George et al. (2025)](https://doi.org/10.1182/blood-2025-1023)
39. [George et al. (2026)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2026-Summit-Correlational.pdf)
40. [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)
41. [Guarnieri et al. (2021)](https://ashpublications.org/blood/article/138/Supplement%201/4595/478022/Preclinical-Data-with-KIT-D816V-Inhibitor)
42. [IQWiG](https://www.iqwig.de/en/projects/a25-136.html)
43. [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)
44. [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)
45. [McMurray et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418066/)
46. [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)
47. [Mesa et al. (2022a)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34420)
48. [Mesa et al. (2022b)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34421)
49. [NCCN (2024)](https://doi.org/10.6004/jnccn.2024.0030)
50. [Norregaard et al. (2021)](https://www.blueprintmedinfo.com/uploads/AMCP-2021.-Non-advanced-SM-poster_.pdf)
51. [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)
52. [Pongdee et al. (2025)](https://www.blueprintmedicines.com/wp-content/uploads/2025/03/Blueprint-Medicines-AAAAI-WAO-2025-ISM-Mayo-Clinic-Electronic-Health-Records-Real-World-Natural-History-Oral-1.pdf)
53. [Pongdee et al. (2026)](https://www.sciencedirect.com/science/article/pii/S2772829326000639)
54. [Rein et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper194551.html)
55. [Rein et al. (2025)](https://ashpublications.org/blood/article/146/Supplement%201/80/548775/Efficacy-and-safety-results-from-the-primary)
56. [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)
57. [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)
58. [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x)
59. [Siebenhaar et al. (2025b)](https://epostersonline-2.s3.amazonaws.com/soho2025/soho2025.41505d6.NORMAL.pdf)
60. [Syal et al. (2025)](https://link.springer.com/article/10.1007/s00277-025-06475-y)
61. [Tse et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372574/)
62. [Valent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659997/)
63. [Zeiger et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39477015/)

## Related pages
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations.md)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses.md)
